Advertisement

Clinical Classification and Incidence of Fulminant and Abortive Malignant Hyperthermia Reactions in Italy

  • V. Tegazzin
  • A. Accorsi
  • I. Moroni
  • D. Di Martino
  • V. Brancadoro
  • V. Peduto
Conference paper

Summary

A study made throughout Italy during the period 1990–1993 by the Malignant Hyperthermia (MH) Laboratory and the Italian MH Registry showed that the incidence of MH reactions in Italy was 1 in 51000. These data are not greatly different from the results reported by anesthesiologists in a retrospective investigation in four regions: Piemonte, Emilia Romagna, Veneto, and Tuscany, where the incidence was found to be about 1 in 70 000–75 000 and only the “very suspected MH reactions (fulminant and abortive)” were considered. The referred signs of MH adverse reactions—fulminant and abortive—were, first of all, tachycardia, arrhythmia, fever, rigidity, high values of creatine kinase (CK), myoglobinuria, acidosis, hypoxia, dark venous bleeding, and, when monitored, high end-tidal (ET) CO2. Following these clinical signs and considering their association with 110 MH reactions, 28 of the probands referred to the MH Italian Registry and to the four MH laboratories in the past 4 years (1990–1993) were classified as fulminant forms and 69 as abortive forms, with an incidence of 1 in 200 000 and 1 in 81000, respectively.

Keywords

Creatine Kinase Soda Lime Malignant Hyperthermia Malignant Hyperthermia Malignant Hyperthermia Susceptibility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 2: 45CrossRefGoogle Scholar
  2. 2.
    Pollazzon G, Salvadego L (1968) Considerazioni sulla ipertonia muscolare—ipertermia maligna in corso di anestesia generale. Acta Anaesthesiol (Padua) 19: 1–7CrossRefGoogle Scholar
  3. 3.
    European MH Group (1984) A protocol for the investigation of malignant hyperpirexia (MH) susceptibility. Br J Anaesth 56: 1267–1271CrossRefGoogle Scholar
  4. 4.
    Frding H (1985) Incidence of malignant hyperthermia in Denmark. Anesth Analg 64: 700–704Google Scholar
  5. 5.
    Hackl W, Mauritz W, Schemper M, Winkler M, Sporn P, Steinbereithner K (1990) Prediction of malignant hyperthermia susceptibility: statistical evaluation of clinical signs. Br J Anaesth 64: 425–429PubMedCrossRefGoogle Scholar
  6. 6.
    Nakao M, Morio M, Mukaida K, Yuge 0 (1990) Incidence of fulminant malignant hyperthermia in Japan. MH Workshop, MunichGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • V. Tegazzin
    • 1
  • A. Accorsi
    • 2
  • I. Moroni
    • 3
  • D. Di Martino
    • 4
  • V. Brancadoro
    • 5
  • V. Peduto
    • 6
  1. 1.MH LaboratoryS. Antonio HospitalPaduaItaly
  2. 2.Italian MH RegistryUSL 25Bentivoglio (Bo)Italy
  3. 3.Neurology InstituteOspedale MaggioreMilanItaly
  4. 4.MH LaboratoryUSL 40NaplesItaly
  5. 5.MH LaboratoryII PoliclinicoNaplesItaly
  6. 6.Department of AnaesthesiaUniversity of CagliariCagliariItaly

Personalised recommendations